Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

PURPOSE: To investigate whether tolerance to the anti-VEGF drug, ranibizumab, develops after drug exposure and to determine whether the history of treatment with ranibizumab prior to refractoriness can predict the post-switching responses to aflibercept. METHODS: We retrospectively investigated neov...

Descripción completa

Detalles Bibliográficos
Autores principales: Dirani, Ali, Mantel, Irmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880512/
https://www.ncbi.nlm.nih.gov/pubmed/29636594
http://dx.doi.org/10.2147/OPTH.S160367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880512/
https://www.ncbi.nlm.nih.gov/pubmed/29636594
http://dx.doi.org/10.2147/OPTH.S160367

Ejemplares similares